Frovatriptan is a 5-HT1B/1D receptor agonist used to treat migraines. Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
- Mechanism
- Curator reviewed
Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
- Primary indication
- For the acute treatment of migraine attacks with or without aura in adults.Curator reviewed · 3 structured indications
- Formula / weight
- C14H17N3O · 243.3043 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2001
- Code names
- SB 209509
- Brand names
Resolves to
XPSQPHWEGNHMSK-SECBINFHSA-NSMILESCN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Frovatriptan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account